Study of AK120 for teens with moderate-to-severe eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new medicine called AK120 in teenagers with moderate-to-severe atopic dermatitis (also known as eczema) that hasn't improved with other treatments. The goal is to see if AK120 can reduce itching and clear skin symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 17 years old.
- You weigh at least 30 kilograms (about 66 pounds).
- You have had eczema for at least 6 months.
- Your eczema covers at least 10% of your body and is considered moderate to severe.
- You have not had certain eye conditions like vernal keratoconjunctivitis or atopic keratoconjunctivitis.
- You have no known allergies to the study drug or to other similar medicines.
- You have not had surgery within the last 4 weeks or plan to have surgery during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called AK120 for teenagers with moderate-to-severe atopic dermatitis (eczema). It aims to see if the drug can reduce itching and improve skin symptoms.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This study tests a new injectable medication called MG-K10 for teens with moderate to severe eczema that hasn't been well controlled with creams. The goal is to see if it can safely reduce inflammation and improve skin symptoms.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
This study tests an oral medication (EC-18) for moderate to severe atopic dermatitis (eczema) to see if it can improve symptoms like itching and skin rash. It may be an option for people whose eczema is not controlled by topical treatments.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.